Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The Angels Initiative

Stroke prevention

  Autoimmune Disorders

  Free Subscription

Articles published in J Neuroimmunol

Retrieve available abstracts of 190 articles:
HTML format

Single Articles

    November 2022
  1. EATON J, Rahmlow M
    Myelin oligodendrocyte glycoprotein associated transverse myelitis following brain abscess: Case report and literature review.
    J Neuroimmunol. 2022;372:577967.
    PubMed     Abstract available

  2. SHU Y, Ma X, Chen C, Wang Y, et al
    Myelin oligodendrocyte glycoprotein-associated disease is associated with BANK1, RNASET2 and TNIP1 polymorphisms.
    J Neuroimmunol. 2022;372:577937.
    PubMed     Abstract available

    October 2022
  3. LI X, Chu Y, Ma R, Dou M, et al
    Ferroptosis as a mechanism of oligodendrocyte loss and demyelination in experimental autoimmune encephalomyelitis.
    J Neuroimmunol. 2022;373:577995.
    PubMed     Abstract available

  4. CUTELLE C, Balducci C, Cereda D, Fusco ML, et al
    K index utility as diagnostic and prognostic biomarker in the assessment of patients with suspected Multiple Sclerosis.
    J Neuroimmunol. 2022;373:577992.
    PubMed     Abstract available

  5. DE SOUZA TIEPPO EM, da Silva TFF, de Araujo RS, Silva GD, et al
    Primary angiitis of the central nervous system as a mimic of multiple sclerosis: A case report.
    J Neuroimmunol. 2022;373:577991.
    PubMed     Abstract available

  6. BEECHER G, Howe BM, Shelly S, Staff NP, et al
    Plexus MRI helps distinguish the immune-mediated neuropathies MADSAM and MMN.
    J Neuroimmunol. 2022;371:577953.
    PubMed     Abstract available

  7. FEIZI P, Sharma K, Pasham SR, Nirwan L, et al
    Central nervous system (CNS) inflammatory demyelinating diseases (IDDs) associated with COVID-19: A case series and review.
    J Neuroimmunol. 2022;371:577939.
    PubMed     Abstract available

  8. VERGOOSSEN DLE, Ruiter AM, Keene KR, Niks EH, et al
    Enrichment of serum IgG4 in MuSK myasthenia gravis patients.
    J Neuroimmunol. 2022;373:577978.
    PubMed     Abstract available

    September 2022
  9. FARAJI J, Gustafson C, Bettenson D, Negoro H, et al
    Bladder dysfunction in experimental autoimmune encephalomyelitis reflects clinical severity: A pilot study.
    J Neuroimmunol. 2022;372:577973.
    PubMed     Abstract available

  10. LAMBE J, McGinley MP, Moss BP, Mao-Draayer Y, et al
    Myelin oligodendrocyte glycoprotein-IgG associated disorders (MOGAD) following SARS-CoV-2 infection: A case series.
    J Neuroimmunol. 2022;370:577933.
    PubMed     Abstract available

  11. KASHYAP N, Morris M, Loerinc LB, Benoit M, et al
    The neutrophil-to-lymphocyte ratio is associated with intubation in pediatric anti-NMDA receptor encephalitis: A retrospective study.
    J Neuroimmunol. 2022;370:577931.
    PubMed     Abstract available

  12. KELLY H, Johnson J, Jakubecz C, Serra A, et al
    Prevalence of iatrogenic CNS inflammation at a tertiary neuroimmunology clinic.
    J Neuroimmunol. 2022;370:577928.
    PubMed     Abstract available

  13. HARAMATI A, Rechtman A, Zveik O, Haham N, et al
    IL-6 as a marker for NMOSD disease activity.
    J Neuroimmunol. 2022;370:577925.
    PubMed     Abstract available

  14. MAGALASHVILI D, Mandel M, Dreyer-Alster S, Didikin M, et al
    Cladribine treatment for highly active multiple sclerosis: Real-world clinical outcomes for years 3 and 4.
    J Neuroimmunol. 2022;372:577966.
    PubMed     Abstract available

    August 2022
  15. WU H, Chen L, Zhou X, Wu Y, et al
    Effect of tacrolimus on soluble costimulatory molecules in patients with refractory myasthenia gravis.
    J Neuroimmunol. 2022;372:577955.
    PubMed     Abstract available

  16. ORTIGOZA-ESCOBAR JD, Fernandez de Sevilla M, Monfort L, Anton J, et al
    Cytokine profile and brain biopsy in a case of childhood-onset central nervous system vasculitis in Noonan syndrome-like disorder due to a novel CBL variant.
    J Neuroimmunol. 2022;369:577917.
    PubMed     Abstract available

  17. JIANG W, Sun X, Huang H, Sun H, et al
    Bilateral parafalcine cortical and leptomeningeal impairment in MOG antibody disease and AQP4 neuromyelitis optica.
    J Neuroimmunol. 2022;369:577898.
    PubMed     Abstract available

  18. NEWSOME SD, Johnson T
    Stiff person syndrome spectrum disorders; more than meets the eye.
    J Neuroimmunol. 2022;369:577915.
    PubMed     Abstract available

    Comment on "SARS-CoV-2 vaccinations may not only be complicated by GBS but also by distal small fiber neuropathy by J. Finsterer.
    J Neuroimmunol. 2022;369:577901.

  20. CAO B, Luo M, Li J, Lu Y, et al
    Cerebrospinal fluid cystatin C levels in patients with anti-NMDAR encephalitis and other neurological diseases.
    J Neuroimmunol. 2022;369:577900.
    PubMed     Abstract available

  21. RACKE MK, Batish SD, Lisak RP, Barohn RJ, et al
    LRP4 antibody testing in myasthenia gravis.
    J Neuroimmunol. 2022;371:577949.

  22. ISHIZUCHI K, Takizawa T, Ohnuki Y, Sekiguchi K, et al
    Immunodeficiency in patients with thymoma-associated myasthenia gravis.
    J Neuroimmunol. 2022;371:577950.
    PubMed     Abstract available

    July 2022
  23. ALOISI F, Cross AH
    MINI-review of Epstein-Barr virus involvement in multiple sclerosis etiology and pathogenesis.
    J Neuroimmunol. 2022;371:577935.
    PubMed     Abstract available

  24. FUCHS L, Mausner-Fainberg K, Luban A, Asseyer SE, et al
    CTGF/CCN2 has a possible detrimental role in the inflammation and the remyelination failure in the early stages of multiple sclerosis.
    J Neuroimmunol. 2022;371:577936.
    PubMed     Abstract available

  25. MURAKAMI K, Miyamoto K, Terayama A, Yoshikawa K, et al
    Acute eye movement-retained internal ophthalmoplegia in atypical Miller Fisher syndrome variants are associated with IgG anti-GQ1b antibodies.
    J Neuroimmunol. 2022;368:577880.
    PubMed     Abstract available

  26. DAS NEVES SP, Serre-Miranda C, Sousa JC, Costa PS, et al
    Lipocalin-2 does not influence EAE clinical score but it increases inflammation in central nervous system.
    J Neuroimmunol. 2022;368:577872.
    PubMed     Abstract available

  27. VAN DER WEELE L, Pollastro S, van Schaik BDC, van Kampen AHC, et al
    Longitudinal analysis of anti-drug antibody development in multiple sclerosis patients treated with interferon beta-1a (Rebif) using B cell receptor repertoire analysis.
    J Neuroimmunol. 2022;370:577932.
    PubMed     Abstract available

  28. FONAGER SV, Winther G, Wittenborn TR, Jensen L, et al
    Increased maternofoetal transfer of antibodies in a murine model of systemic lupus erythematosus, but no immune activation and neuroimmune sequelae in offspring.
    J Neuroimmunol. 2022;370:577927.
    PubMed     Abstract available

  29. KASHEKE GDS, Holman SP, Robertson GS
    Fingolimod attenuates gait deficits in mice subjected to experimental autoimmune encephalomyelitis.
    J Neuroimmunol. 2022;370:577926.
    PubMed     Abstract available

  30. STRIJBOS E, van Ostaijen-Ten Dam MM, Vervat C, Schilham MW, et al
    The effect of immunosuppression or thymectomy on the response to tetanus revaccination in myasthenia gravis.
    J Neuroimmunol. 2022;370:577930.
    PubMed     Abstract available

    June 2022
  31. WEIHUA Z, Haitao R, Jie D, Changhong R, et al
    Autoimmune cerebellar ataxia associated with anti-leucine-rich glioma-inactivated protein 1 antibodies: Two pediatric cases.
    J Neuroimmunol. 2022;370:577918.
    PubMed     Abstract available

  32. RACKE MK, Niles JK, Lorenz RA, Kaufman HW, et al
    Changes in ganglioside antibody positivity rates during the COVID-19 pandemic.
    J Neuroimmunol. 2022;367:577877.
    PubMed     Abstract available

  33. NIE DA, Abud A, Serrano-Gonzalez M, Harappanahally G, et al
    Pediatric stiff limb syndrome with polyautoimmunity of anti-GAD-65, anti-islet cell, and thyroid peroxidase antibodies: A case report and review of literature.
    J Neuroimmunol. 2022;367:577865.
    PubMed     Abstract available

  34. MASI G, Li Y, Karatz T, Pham MC, et al
    The clinical need for clustered AChR cell-based assay testing of seronegative MG.
    J Neuroimmunol. 2022;367:577850.
    PubMed     Abstract available

  35. HU K, Yang Y, Liu J, Chen X, et al
    Susac syndrome with the typical clinical triad: A case report and literature review.
    J Neuroimmunol. 2022;367:577822.
    PubMed     Abstract available

  36. YAO Y, Zhang O, Gu L, Zhang X, et al
    Analysis of risk factors for a poor functional prognosis and relapse in patients with autoimmune encephalitis.
    J Neuroimmunol. 2022;369:577899.
    PubMed     Abstract available

  37. CHAN F, Riminton DS, Ramanathan S, Reddel SW, et al
    Distinguishing CNS neurosarcoidosis from multiple sclerosis and an approach to "overlap" cases.
    J Neuroimmunol. 2022;369:577904.
    PubMed     Abstract available

    May 2022
  38. YAO Y, Uddin MN, Manley K, Lawrence DA, et al
    Improvements of autism-like behaviors but limited effects on immune cell metabolism after mitochondrial replacement in BTBR T(+)Itpr3(tf)/J mice.
    J Neuroimmunol. 2022;368:577893.
    PubMed     Abstract available

  39. KLEIN CJ, Beecher G, Lamb C, Naddaf E, et al
    LRP4-IgG service line testing in seronegative myasthenia gravis and controls.
    J Neuroimmunol. 2022;368:577895.
    PubMed     Abstract available

  40. PAUL SA, Roy D, Mondal GP, Bhattacharyya R, et al
    Primary angiitis of central nervous system - A challenging diagnosis.
    J Neuroimmunol. 2022;366:577844.
    PubMed     Abstract available

  41. DINOTO A, McKeon A, Vattemi G, Carta S, et al
    Neuronal intermediate filament paraneoplastic autoimmunity complicating avelumab therapy of Merkel cell carcinoma.
    J Neuroimmunol. 2022;368:577882.
    PubMed     Abstract available

  42. GILL AJ, Venkatesan A
    Pathogenic mechanisms in neuronal surface autoantibody-mediated encephalitis.
    J Neuroimmunol. 2022;368:577867.
    PubMed     Abstract available

    April 2022
  43. WANG J, Jin L, Zhang X, Yu H, et al
    Activated microglia by (18)F-DPA714 PET in a case of anti-LGI1 autoimmune encephalitis.
    J Neuroimmunol. 2022;368:577879.
    PubMed     Abstract available

  44. FERILLI MAN, Papi C, Sabatelli M, Colosimo C, et al
    MOG autoimmunity mimicking CLIPPERS syndrome: Case report and literature review.
    J Neuroimmunol. 2022;367:577875.
    PubMed     Abstract available

  45. MA R, Chu Y, Dou M, Jing Y, et al
    Matrine inhibits the Wnt3a/beta-catenin/TCF7L2 signaling pathway in experimental autoimmune encephalomyelitis.
    J Neuroimmunol. 2022;367:577876.
    PubMed     Abstract available

  46. KYLLESBECH C, Trier N, Slibinskas R, Ciplys E, et al
    Virus-specific antibody indices may supplement the total IgG index in diagnostics of multiple sclerosis.
    J Neuroimmunol. 2022;367:577868.
    PubMed     Abstract available

  47. ODA F, Uzawa A, Ozawa Y, Yasuda M, et al
    Serum cytokine and chemokine profiles in patients with immune-mediated necrotizing myopathy.
    J Neuroimmunol. 2022;365:577833.
    PubMed     Abstract available

  48. DEKEYSER C, Naesens L, Offner F, De Vriendt C, et al
    A unique phenotype of longitudinal extensive transverse myelitis in autoimmune lymphoproliferative syndrome.
    J Neuroimmunol. 2022;367:577866.
    PubMed     Abstract available

  49. MCKEON-MAKKI I, McKeon A, Yang B, Pittock SJ, et al
    Adenylate kinase 5 (AK5) autoimmune encephalitis: Clinical presentations and outcomes in three new patients.
    J Neuroimmunol. 2022;367:577861.
    PubMed     Abstract available

    March 2022
  50. JIN J, Shneyderman M, Smith MD, Gharagozloo M, et al
    Retinal pathology in spontaneous opticospinal experimental autoimmune encephalitis mice.
    J Neuroimmunol. 2022;367:577859.
    PubMed     Abstract available

  51. TOTTENHAM I, Koch M, Camara-Lemarroy C
    Serum HGF and APN2 are associated with disability worsening in SPMS.
    J Neuroimmunol. 2022;364:577803.
    PubMed     Abstract available

  52. NEPAL G, Kharel S, Coghlan MA, Rayamajhi P, et al
    Safety and efficacy of rituximab for relapse prevention in myelin oligodendrocyte glycoprotein immunoglobulin G (MOG-IgG)-associated disorders (MOGAD): A systematic review and meta-analysis.
    J Neuroimmunol. 2022;364:577812.
    PubMed     Abstract available

  53. WENG J, Du Z, Zhang Y
    CNS limited ANCA-associated vasculitis presenting as an isolated intraparenchymal mass.
    J Neuroimmunol. 2022;364:577791.
    PubMed     Abstract available

  54. DIAZ P, Leveque M, Hautecloque G, Sellal F, et al
    The challenge of diagnosing Guillain-Barre syndrome in patients with COVID-19 in the intensive care unit.
    J Neuroimmunol. 2022;366:577842.
    PubMed     Abstract available

  55. SALARI AA, Jand Y, Ghazi-Khansari M
    Antibiotic treatment during pregnancy and lactation in dams exacerbates clinical symptoms and inflammatory responses in offspring with experimental autoimmune encephalomyelitis.
    J Neuroimmunol. 2022;366:577840.
    PubMed     Abstract available

    February 2022
  56. MA J, Yu H, Wang H, Zhang X, et al
    Evaluation of effect of empirical attack-preventive immunotherapies in neuromyelitis optica spectrum disorders: An update systematic review and meta -analysis.
    J Neuroimmunol. 2022;363:577790.
    PubMed     Abstract available

  57. COSTA D, Sardoeira A, Carneiro P, Neves E, et al
    Autoimmune encephalitis: suspicion in clinical practice and mimics.
    J Neuroimmunol. 2022;365:577824.
    PubMed     Abstract available

    January 2022
  58. MOLLER L, Kerwat M, Timmermann L, Simon OJ, et al
    When your cat takes you to the ICU: Miller Fisher/ Guillain-Barre-overlap-syndrome caused by Pasteurella multocida infection resembling wound botulism.
    J Neuroimmunol. 2022;365:577821.
    PubMed     Abstract available

  59. ISMAIL II, Salama S
    A systematic review of cases of CNS demyelination following COVID-19 vaccination.
    J Neuroimmunol. 2022;362:577765.
    PubMed     Abstract available

  60. MA X, Chen C, Fang L, Zhong X, et al
    Dysregulated CD40 and CD40 ligand expression in anti-N-methyl-d-aspartate receptor encephalitis.
    J Neuroimmunol. 2022;362:577762.
    PubMed     Abstract available

  61. KADISH R, Clardy SL, Royston M, Tanvir I, et al
    Clinical burden of relapses in aquaporin-4 immunoglobulin G-positive neuromyelitis optica spectrum disorder: A single center cohort analysis.
    J Neuroimmunol. 2022;362:577761.
    PubMed     Abstract available

  62. KALININ S, Boullerne AI, Feinstein DL
    Serum levels of lipocalin-2 are elevated at early times in African American relapsing remitting multiple sclerosis patients.
    J Neuroimmunol. 2022;364:577810.
    PubMed     Abstract available

  63. YE F, Dai Y, Wang T, Liang J, et al
    Trans-omics analyses revealed key epigenetic genes associated with overall survival in secondary progressive multiple sclerosis.
    J Neuroimmunol. 2022;364:577809.
    PubMed     Abstract available

  64. BRORSON IS, Eriksson AM, Hogestol E, Leikfoss IS, et al
    Global DNA methylation changes in treated and untreated MS patients measured over time.
    J Neuroimmunol. 2022;364:577808.
    PubMed     Abstract available

  65. URRIOLA N, Blazek K, Adelstein S
    Subunit-specific autoantibodies in autoimmune autonomic ganglionopathy.
    J Neuroimmunol. 2022;363:577805.
    PubMed     Abstract available

    December 2021
  66. RONCHI NR, Silva GD
    Comparison of the clinical syndromes of anti-GABAa versus anti-GABAb associated autoimmune encephalitis: A systematic review.
    J Neuroimmunol. 2021;363:577804.
    PubMed     Abstract available

  67. DIAS DA COSTA M, Leal Rato M, Cruz D, Valadas A, et al
    Longitudinally extensive transverse myelitis with anti-myelin oligodendrocyte glycoprotein antibodies following SARS-CoV-2 infection.
    J Neuroimmunol. 2021;361:577739.
    PubMed     Abstract available

  68. THOLANCE Y, Antoine JC, Mohr L, Jung M, et al
    Anti-FGFR3 antibody epitopes are functional sites and correlate with the neuropathy pattern.
    J Neuroimmunol. 2021;361:577757.
    PubMed     Abstract available

  69. TALBOT J, Hojsgaard Chow H, Holm Hansen R, von Essen MR, et al
    Immunological effects of dimethyl fumarate treatment in blood and CSF of patients with primary progressive MS.
    J Neuroimmunol. 2021;361:577756.
    PubMed     Abstract available

  70. REN H, Fan S, Zhao Y, Guan H, et al
    The changing spectrum of antibody-mediated encephalitis in China.
    J Neuroimmunol. 2021;361:577753.
    PubMed     Abstract available

  71. PUJARI SS, Kulkarni RV, Ojha P, Gursahani R, et al
    Acute haemorrhagic leukoencephalitis (AHLE) - our experience and a short review.
    J Neuroimmunol. 2021;361:577751.
    PubMed     Abstract available

  72. DIAS L, Barbosa L, Martins F, Braz L, et al
    Risk factors for idiopathic myelitis at admission and predictors for late diagnostic change.
    J Neuroimmunol. 2021;361:577747.
    PubMed     Abstract available

  73. SAHA S, Mukherjee S, Guha G, Mukhopadhyay D, et al
    Dynamics of AQP4 upon exposure to seropositive patient serum before and after Rituximab therapy in Neuromyelitis Optica: A cell-based study.
    J Neuroimmunol. 2021;361:577752.
    PubMed     Abstract available

  74. NAGIREDDY RBR, Kumar A, Singh VK, Prasad R, et al
    Clinicoradiological comparative study of Aquaporin-4-IgG seropositive neuromyelitis optica spectrum disorder (NMOSD) and MOG antibody associated disease (MOGAD): A prospective observational study and review of literature.
    J Neuroimmunol. 2021;361:577742.
    PubMed     Abstract available

  75. KESHVARI MK, van Someren F, Sheikh S, Galea I, et al
    Eosinophilia during natalizumab treatment: Incidence, risk factors and temporal patterns.
    J Neuroimmunol. 2021;361:577729.
    PubMed     Abstract available

  76. STECK AJ
    Anti-MAG neuropathy: From biology to clinical management.
    J Neuroimmunol. 2021;361:577725.
    PubMed     Abstract available

  77. ADAMEC I, Rogic D, Penz MG, Braun C, et al
    Humoral and cellular immunity in convalescent COVID-19 people with multiple sclerosis treated with ofatumumab.
    J Neuroimmunol. 2021;362:577788.
    PubMed     Abstract available

  78. SONG J, Yang J, Jing S, Yan C, et al
    Berberine attenuates experimental autoimmune myasthenia gravis via rebalancing the T cell subsets.
    J Neuroimmunol. 2021;362:577787.
    PubMed     Abstract available

  79. TOLJAN K, Amin M, Kunchok A, Ontaneda D, et al
    New diagnosis of multiple sclerosis in the setting of mRNA COVID-19 vaccine exposure.
    J Neuroimmunol. 2021;362:577785.
    PubMed     Abstract available

    November 2021
  80. CHEN B, Tian DS, Bu BT
    Immunological predictors for the outcome in patients with antibody-mediated autoimmune encephalitis.
    J Neuroimmunol. 2021;362:577779.
    PubMed     Abstract available

    Comments on "Initial clinical manifestation of multiple sclerosis after immunization with the Pfizer-BioNTech COVID-19 vaccine" by , J Neuroimmunol.
    J Neuroimmunol. 2021;362:577780.

  82. WUERCH E, Mishra M, Melo H, Ebacher V, et al
    Quantitative analysis of spinal cord neuropathology in experimental autoimmune encephalomyelitis.
    J Neuroimmunol. 2021;362:577777.
    PubMed     Abstract available

  83. JIAO L, Li H, Guo S
    Eculizumab treatment for myasthenia gravis subgroups: 2021 update.
    J Neuroimmunol. 2021;362:577767.
    PubMed     Abstract available

  84. HWANG D, Boehm A, Rostami A, Zhang GX, et al
    Oral D-mannose treatment suppresses experimental autoimmune encephalomyelitis via induction of regulatory T cells.
    J Neuroimmunol. 2021;362:577778.
    PubMed     Abstract available

  85. HASSANSHAHI G, Noroozi Karimabad M, Jebali A
    The therapeutic effect of PEGlated nanoliposome of pistachio unsaturated oils and its efficacy to attenuate inflammation in multiple sclerosis: A randomized, double-blind, placebo-controlled clinical trial phase I.
    J Neuroimmunol. 2021;362:577768.
    PubMed     Abstract available

    SARS-CoV-2 vaccinations may not only be complicated by GBS but also by distal small fibre neuropathy.
    J Neuroimmunol. 2021;360:577703.

  87. POURMOGHADDAS Z, Sadeghizadeh A, Tara SZ, Zandifar A, et al
    Longitudinally extensive transverse myelitis as a sign of multisystem inflammatory syndrome following COVID-19 infection: A pediatric case report.
    J Neuroimmunol. 2021;360:577704.
    PubMed     Abstract available

  88. MOLAZADEH N, Filippatou AG, Vasileiou ES, Levy M, et al
    Evidence for and against subclinical disease activity and progressive disease in MOG antibody disease and neuromyelitis optica spectrum disorder.
    J Neuroimmunol. 2021;360:577702.
    PubMed     Abstract available

  89. FREEDMAN MS, Wojcik J, Holmberg KH, Fluck M, et al
    Pharmacodynamic biomarkers of long-term interferon beta-1a therapy in REFLEX and REFLEXION.
    J Neuroimmunol. 2021;360:577715.
    PubMed     Abstract available

  90. NILLES C, Poillon G, Deschamps L, Daval M, et al
    IgG4-related pachymeningitis and mastoiditis, associated with cerebral venous thrombosis: A case report.
    J Neuroimmunol. 2021;360:577717.
    PubMed     Abstract available

  91. PANDIT L, Malli C, D'Cunha A, Sudhir A, et al
    Overcoming the challenges in diagnosis of AQP4-IgG positive neuromyelitis optica spectrum disorders in resource poor settings using an indigenized and cost effective cell based assay.
    J Neuroimmunol. 2021;360:577706.
    PubMed     Abstract available

  92. PACHE F, Ringelstein M, Aktas O, Kleiter I, et al
    C3 and C4 complement levels in AQP4-IgG-positive NMOSD and in MOGAD.
    J Neuroimmunol. 2021;360:577699.
    PubMed     Abstract available

  93. MASCIA E, Clarelli F, Zauli A, Guaschino C, et al
    Burden of rare coding variants in an Italian cohort of familial multiple sclerosis.
    J Neuroimmunol. 2021;362:577760.
    PubMed     Abstract available

    October 2021
  94. VAKRAKOU AG, Tzanetakos D, Evangelopoulos ME, Fragoulis GE, et al
    IgG4-related autoimmune manifestations in Alemtuzumab-treated multiple sclerosis patients.
    J Neuroimmunol. 2021;361:577759.
    PubMed     Abstract available

  95. FUJIMORI J, Miyazawa K, Nakashima I
    Initial clinical manifestation of multiple sclerosis after immunization with the Pfizer-BioNTech COVID-19 vaccine.
    J Neuroimmunol. 2021;361:577755.
    PubMed     Abstract available

  96. ZELADA-RIOS L, Pacheco-Barrios K, Galecio-Castillo M, Yamunaque-Chunga C, et al
    Acute disseminated encephalomyelitis and COVID-19: A systematic synthesis of worldwide cases.
    J Neuroimmunol. 2021;359:577674.
    PubMed     Abstract available

  97. SRIWASTAVA S, Lisak RP
    Acetylcholine receptor antibodies in a patient with sensory neuropathy.
    J Neuroimmunol. 2021;359:577692.
    PubMed     Abstract available

  98. TANG H, Wang L, Zhou H, Hao X, et al
    Psychiatric symptoms as initial manifestation in neuromyelitis optica spectrum disorder without cortical lesions: A report of two cases.
    J Neuroimmunol. 2021;359:577693.
    PubMed     Abstract available

  99. GOI LDS, Altenhofen S, Nabinger DD, Bonan CD, et al
    Decreased convulsive threshold and memory loss after anti-NMDAR positive CSF injection in zebrafish.
    J Neuroimmunol. 2021;359:577689.
    PubMed     Abstract available

  100. OTA S, Kotani T, Matsuda S, Nishioka D, et al
    Initial serum GM-CSF levels are associated with the severity of cerebral small vessel disease in microscopic polyangiitis patients.
    J Neuroimmunol. 2021;359:577671.
    PubMed     Abstract available

  101. SANTIAGO JA, Babico M, Stitt G, Thomas CA, et al
    Low-dose intrathecal rituximab is a safe and potentially effective treatment for pediatric neuroimmunologic disorders.
    J Neuroimmunol. 2021;359:577687.
    PubMed     Abstract available

  102. ACHIRON A, Mandel M, Dreyer-Alster S, Harari G, et al
    Humoral immune response in multiple sclerosis patients following PfizerBNT162b2 COVID19 vaccination: Up to 6 months cross-sectional study.
    J Neuroimmunol. 2021;361:577746.
    PubMed     Abstract available

  103. KIMURA A, Kato S, Takekoshi A, Yoshikura N, et al
    Autoimmune glial fibrillary acidic protein astrocytopathy resembling isolated central nervous system lymphomatoid granulomatosis.
    J Neuroimmunol. 2021;361:577748.
    PubMed     Abstract available

  104. CHE NN, Chen SY, Li X, Ma JJ, et al
    Autoimmune-mediated secondary-parkinsonism presented with micrographia and cognitive impairment.
    J Neuroimmunol. 2021;361:577738.
    PubMed     Abstract available

  105. SEGAL JP, Phillips S, Dubois RM, Silva JR, et al
    Weight bearing as a measure of disease progression in experimental autoimmune encephalomyelitis.
    J Neuroimmunol. 2021;361:577730.
    PubMed     Abstract available

    September 2021
  106. OO WM, Giri P, de Souza A
    AstraZeneca COVID-19 vaccine and Guillain- Barre Syndrome in Tasmania: A causal link?
    J Neuroimmunol. 2021;360:577719.
    PubMed     Abstract available

    Commentary: The spectrum of neurological manifestations related to COVID-19 and vaccinations.
    J Neuroimmunol. 2021;358:577660.

  108. GHOSH R, Dubey S, Mandal A, Ray BK, et al
    Complex movement disorders in SARS-CoV-2 infection induced acute disseminated encephalomyelitis.
    J Neuroimmunol. 2021;358:577655.
    PubMed     Abstract available

  109. PAGENKOPF C, Sudmeyer M
    A case of longitudinally extensive transverse myelitis following vaccination against Covid-19.
    J Neuroimmunol. 2021;358:577606.
    PubMed     Abstract available

  110. SRIWASTAVA S, Kataria S, Srivastava S, Kazemlou S, et al
    Disease-modifying therapies and progressive multifocal leukoencephalopathy in multiple sclerosis: A systematic review and meta-analysis.
    J Neuroimmunol. 2021;360:577721.
    PubMed     Abstract available

  111. VAN LIEVERLOO GGA, Wieske L, van Schaik IN, Deijs M, et al
    Virus discovery in chronic inflammatory demyelinating polyneuropathy.
    J Neuroimmunol. 2021;358:577668.
    PubMed     Abstract available

  112. MORCH MT, Khorooshi R, Marczynska J, Dubik M, et al
    Mitochondria-A target for attenuation of astrocyte pathology.
    J Neuroimmunol. 2021;358:577657.
    PubMed     Abstract available

  113. SECHI E, Zarbo R, Biancu MA, Chessa P, et al
    Prolonged B-cell depletion after rituximab in AQP4-IgG-positive neuromyelitis optica spectrum disorder.
    J Neuroimmunol. 2021;358:577666.
    PubMed     Abstract available

  114. ZHAO X, Yang P
    Hydroxychloroquine alleviates the neurotoxicity induced by anti-ribosomal P antibodies.
    J Neuroimmunol. 2021;358:577648.
    PubMed     Abstract available

  115. BAEK SH, Kim B, Shin JY, Choi SJ, et al
    EBI2-expressing B cells in neuromyelitis optica spectrum disorder with AQP4-IgG: Association with acute attacks and serum cytokines.
    J Neuroimmunol. 2021;358:577637.
    PubMed     Abstract available

  116. GOMBOLAY GY, Gadde JA
    Aseptic meningitis and leptomeningeal enhancement associated with anti-MOG antibodies: A review.
    J Neuroimmunol. 2021;358:577653.
    PubMed     Abstract available

  117. XIAO J, Chen X, Shang K, Tang Y, et al
    Clinical, neuroradiological, diagnostic and prognostic profile of autoimmune glial fibrillary acidic protein astrocytopathy: A pooled analysis of 324 cases from published data and a single-center retrospective study.
    J Neuroimmunol. 2021;360:577718.
    PubMed     Abstract available

  118. PHILLIPS O, Tubre T, Lorenco H, Batish SD, et al
    Limbic encephalitis in a child with ovarian teratoma and influenza B. Case report and critical review of the history of autoimmune anti-N-methyl-d-aspartate receptor encephalitis.
    J Neuroimmunol. 2021;360:577716.
    PubMed     Abstract available

    August 2021
  119. HAYASHI F, Isobe N, Cossu D, Yokoyama K, et al
    Elevated mycobacterium avium subsp. paratuberculosis (MAP) antibody titer in Japanese multiple sclerosis.
    J Neuroimmunol. 2021;360:577701.
    PubMed     Abstract available

  120. FARSHBAFNADI M, Agah E, Rezaei N
    The second brain: The connection between gut microbiota composition and multiple sclerosis.
    J Neuroimmunol. 2021;360:577700.
    PubMed     Abstract available

  121. RIBES GARCIA S, Casanova Estruch B, Gomez Pajares F, Juan Blanco MA, et al
    Prognostic utility of the IgM oligoclonal bands against myelin lipids in multiple sclerosis.
    J Neuroimmunol. 2021;359:577698.
    PubMed     Abstract available

  122. BRAINER-LIMA JPM, Leite BHS, de Araujo CMCS, Dhalia R, et al
    Are Zika virus cross-reactive antibodies against aquaporin-4 associated to Neuromyelitis Optica Spectrum Disorder?
    J Neuroimmunol. 2021;360:577697.
    PubMed     Abstract available

  123. HABEK M, Jakob Brecl G, Basic Kes V, Rogic D, et al
    Humoral immune response in convalescent COVID-19 people with multiple sclerosis treated with high-efficacy disease-modifying therapies: A multicenter, case-control study.
    J Neuroimmunol. 2021;359:577696.
    PubMed     Abstract available

  124. QIAO X, Wang H, Lu L, Chen J, et al
    Hippocampal microglia CD40 mediates NPSLE cognitive dysfunction in mice.
    J Neuroimmunol. 2021;357:577620.
    PubMed     Abstract available

  125. CHAKRABORTY AP, Pandit A, Ray BK, Mukherjee A, et al
    Capgras syndrome and confabulation unfurling anti NMDAR encephalitis with classical papillary thyroid carcinoma: First reported case.
    J Neuroimmunol. 2021;357:577611.
    PubMed     Abstract available

  126. EQUIZA J, Rodriguez-Antiguedad J, Campo-Caballero D, Iruzubieta P, et al
    Autoimmune GFAP astrocytopathy presenting with remarkable CNS hyperexcitability and oculogyric crises.
    J Neuroimmunol. 2021;359:577695.
    PubMed     Abstract available

  127. COSSU D, Yokoyama K, Sato S, Noda S, et al
    PARKIN modifies peripheral immune response and increases neuroinflammation in active experimental autoimmune encephalomyelitis (EAE).
    J Neuroimmunol. 2021;359:577694.
    PubMed     Abstract available

  128. MIN YG, Ju W, Ha YE, Ban JJ, et al
    Sensory Guillain-Barre syndrome following the ChAdOx1 nCov-19 vaccine: Report of two cases and review of literature.
    J Neuroimmunol. 2021;359:577691.
    PubMed     Abstract available

  129. HAHAM N, Vaknin-Dembinsky A
    COVID-19 in Cladribine-treated patient with multiple sclerosis.
    J Neuroimmunol. 2021;359:577690.
    PubMed     Abstract available

    July 2021
  130. KRAUS EE, Kakuk-Atkins L, Farinas MF, Jeffers M, et al
    Regulation of autoreactive CD4 T cells by FoxO1 signaling in CNS autoimmunity.
    J Neuroimmunol. 2021;359:577675.
    PubMed     Abstract available

  131. LOVETT-RACKE AE, Yang Y, Liu Y, Gormley M, et al
    B cell depletion changes the immune cell profile in multiple sclerosis patients: One-year report.
    J Neuroimmunol. 2021;359:577676.
    PubMed     Abstract available

  132. LAI QL, Cai MT, Zheng Y, Zhang TY, et al
    Seasonal variation in autoimmune encephalitis: A multi-center retrospective study.
    J Neuroimmunol. 2021;359:577673.
    PubMed     Abstract available

  133. YAO Y, Li X, Lin J, Zhang X, et al
    Thymoma-associated autoimmune encephalitis with positive Titin antibodies: A case report.
    J Neuroimmunol. 2021;358:577670.
    PubMed     Abstract available

  134. GUO L, Ren H, Fan S, Guan H, et al
    Autoantibody against the Rab6A/Rab6B in primary autoimmune cerebellar ataxia associated with Sjogren's syndrome: A case report.
    J Neuroimmunol. 2021;359:577667.
    PubMed     Abstract available

  135. WANG J, Yan C, Zhao Z, Chen H, et al
    Sexual dysfunction in patients with myasthenia gravis.
    J Neuroimmunol. 2021;358:577669.
    PubMed     Abstract available

  136. CAPARO-ZAMALLOA C, Alvarez-Toledo K, Yamunaque-Chunga C, Castro-Suarez S, et al
    Autoimmune neurology: Co-occurrence of anti-NMDAR encephalitis and anti-MOG associated disease, report of a case.
    J Neuroimmunol. 2021;358:577663.
    PubMed     Abstract available

  137. LOCKHART A, Boers P
    Paraneoplastic neurologic syndromes with multiple neural autoantibodies: A report of two cases.
    J Neuroimmunol. 2021;358:577665.
    PubMed     Abstract available

  138. LI R, Wang J, Li C, Liu X, et al
    Rescue immunoadsorption treatment for neuromyelitis optica spectrum disorder attacks unresponsive to intravenous methylprednisolone.
    J Neuroimmunol. 2021;356:577604.
    PubMed     Abstract available

  139. DINOTO A, Cheli M, Bratina A, Sartori A, et al
    Bortezomib in anti-N-Methyl-d-Aspartate-Receptor (NMDA-R) encephalitis: A systematic review.
    J Neuroimmunol. 2021;356:577586.
    PubMed     Abstract available

  140. NARESH K, Miraclin TA, Prabhakar AT, Mathew V, et al
    Epstein-Barr virus infection in a woman with aquaporin-4 seropositive neuromyelitis optica.
    J Neuroimmunol. 2021;356:577581.
    PubMed     Abstract available

  141. WONG CK, Hor JY, Loo YP, Heng HS, et al
    High incidence of NMDAR encephalitis among Austronesians: A population-based study in Sabah, Malaysia.
    J Neuroimmunol. 2021;356:577584.
    PubMed     Abstract available

  142. HONGO Y, Kaida K, Komuta Y, Takazaki H, et al
    Cholesterol-added antigens can enhance antiglycolipid antibody activity: Application to antibody testing.
    J Neuroimmunol. 2021;356:577580.
    PubMed     Abstract available

  143. NISHRI Y, Fainstein N, Goldfarb S, Hampton D, et al
    Modeling compartmentalized chronic immune-mediated demyelinating CNS disease in the Biozzi ABH mouse.
    J Neuroimmunol. 2021;356:577582.
    PubMed     Abstract available

  144. MIMPEN M, Damoiseaux J, van Doorn W, Rolf L, et al
    Proportions of circulating transitional B cells associate with MRI activity in interferon beta-treated multiple sclerosis patients.
    J Neuroimmunol. 2021;358:577664.
    PubMed     Abstract available

  145. CORTES-VICENTE E, Alvarez-Velasco R, Illa I, Gallardo E, et al
    Comment to "Autoantibodies to cortactin and agrin in sera of patients with myasthenia gravis".
    J Neuroimmunol. 2021;358:577659.

  146. IVANOVA M, Voronkova A, Sukhorukov V, Zakharova M, et al
    Different neuroinflammatory gene expression profiles in highly active and benign multiple sclerosis.
    J Neuroimmunol. 2021;358:577650.
    PubMed     Abstract available

  147. KHANMOHAMMADI S, Malekpour M, Jabbari P, Rezaei N, et al
    Genetic basis of Guillain-Barre syndrome.
    J Neuroimmunol. 2021;358:577651.
    PubMed     Abstract available

    June 2021
  148. MOSTAFA GA, Meguid NA, Shehab AAS, Elsaeid A, et al
    Plasma levels of nerve growth factor in Egyptian autistic children: Relation to hyperserotonemia and autoimmunity.
    J Neuroimmunol. 2021;358:577638.
    PubMed     Abstract available

  149. MIRZAEI R, Zamani F, Hajibaba M, Rasouli-Saravani A, et al
    The pathogenic, therapeutic and diagnostic role of exosomal microrna in the autoimmune diseases.
    J Neuroimmunol. 2021;358:577640.
    PubMed     Abstract available

  150. JAKHMOLA S, Upadhyay A, Jain K, Mishra A, et al
    Herpesviruses and the hidden links to Multiple Sclerosis neuropathology.
    J Neuroimmunol. 2021;358:577636.
    PubMed     Abstract available

  151. UZAWA A, Akamine H, Kojima Y, Ozawa Y, et al
    High levels of serum interleukin-6 are associated with disease activity in myasthenia gravis.
    J Neuroimmunol. 2021;358:577634.
    PubMed     Abstract available

    Steroid-responsive, transverse myelitis is a known complication of COVID-19.
    J Neuroimmunol. 2021;355:577566.

  153. LEE JK, Kwon S, Han JH, Yoon SE, et al
    Increased proportion of CD20+ T cells after rituximab treatment in patient with neuromyelitis optica later diagnosed with lung B-cell lymphoma: A case report.
    J Neuroimmunol. 2021;355:577564.
    PubMed     Abstract available

  154. GOVIL-DALELA T, Datta I, Williams M
    Refractory NMDA-receptor encephalitis in a teenager: A novel use of Bortezomib.
    J Neuroimmunol. 2021;355:577565.
    PubMed     Abstract available

  155. SON H, Lee WJ, Moon J, Yoon S, et al
    Isolated CNS involvement in eosinophilic granulomatosis with polyangiitis treated with mepolizumab: A case report.
    J Neuroimmunol. 2021;355:577551.
    PubMed     Abstract available

  156. REYES S, Cunningham AL, Kalincik T, Havrdova EK, et al
    Update on the management of multiple sclerosis during the COVID-19 pandemic and post pandemic: An international consensus statement.
    J Neuroimmunol. 2021;357:577627.
    PubMed     Abstract available

  157. FINSTERER J, Ghosh R
    Dimensions of SARS-CoV-2 associated Guillain-Barre syndrome.
    J Neuroimmunol. 2021;357:577626.

  158. NIINO M, Fukazawa T, Miyazaki Y, Ura S, et al
    Seasonal fluctuations in serum levels of vitamin D in Japanese patients with multiple sclerosis.
    J Neuroimmunol. 2021;357:577624.
    PubMed     Abstract available

    May 2021
  159. GRISANTI SG, Franciotta D, Garnero M, Zuppa A, et al
    A case series of parainfectious Guillain-Barre syndrome linked to influenza A (H1N1) virus infection.
    J Neuroimmunol. 2021;357:577605.
    PubMed     Abstract available

  160. MANOUCHEHRI N, Guisso DR, Hussain RZ, Minassian BA, et al
    The antioxidant MnTBAP does not effectively downregulate CD4 expression in T cells in vivo.
    J Neuroimmunol. 2021;354:577544.
    PubMed     Abstract available

  161. WANG T, Wang B, Zeng Z, Li H, et al
    Efficacy and safety of bortezomib in rituximab-resistant anti-N-methyl-d-aspartate receptor (anti-NMDAR) encephalitis as well as the clinical characteristics: An observational study.
    J Neuroimmunol. 2021;354:577527.
    PubMed     Abstract available

  162. FINSTERER J, Scorza FA, Scorza CA, Fiorini AC, et al
    Diagnosing SARS-CoV-2 associated Guillain-Barre syndrome requires cerebro-spinal-fluid studies.
    J Neuroimmunol. 2021;357:577609.

  163. SVIRIDOVA A, Rogovskii V, Kudrin V, Pashenkov M, et al
    The role of 5-HT2B-receptors in fluoxetine-mediated modulation of Th17- and Th1-cells in multiple sclerosis.
    J Neuroimmunol. 2021;356:577608.
    PubMed     Abstract available

  164. ROTOLO RA, Demuro J, Drummond G, Little C, et al
    Prophylactic exposure to oral riluzole reduces the clinical severity and immune-related biomarkers of experimental autoimmune encephalomyelitis.
    J Neuroimmunol. 2021;356:577603.
    PubMed     Abstract available

  165. SOLTANMORADI S, Tavakolpour V, Moghadasi AN, Kouhkan F, et al
    Expression analysis of NF-kappaB-associated long noncoding RNAs in peripheral blood mononuclear cells from relapsing-remitting multiple sclerosis patients.
    J Neuroimmunol. 2021;356:577602.
    PubMed     Abstract available

  166. KELLY H, Sokola B, Abboud H
    Safety and efficacy of COVID-19 vaccines in multiple sclerosis patients.
    J Neuroimmunol. 2021;356:577599.
    PubMed     Abstract available

  167. ZULIANI L, Marangoni S, De Gaspari P, Rosellini I, et al
    Epidemiology of neuronal surface antibody-mediated autoimmune encephalitis and antibody-based diagnostics.
    J Neuroimmunol. 2021 May 1:577598. doi: 10.1016/j.jneuroim.2021.577598.
    PubMed     Abstract available

    April 2021
  168. YOKOTE H
    Author's response in reply to "Question about data: Importance of serum amyloid A level in patients with multiple sclerosis".
    J Neuroimmunol. 2021;356:577589.

  169. DOPPLER K, Hemprich A, Haarmann A, Brecht I, et al
    Autoantibodies to cortactin and agrin in sera of patients with myasthenia gravis.
    J Neuroimmunol. 2021;356:577588.
    PubMed     Abstract available

  170. GARCIA-MANTEIGA JM, Clarelli F, Bonfiglio S, Mascia E, et al
    Identification of differential DNA methylation associated with multiple sclerosis: A family-based study.
    J Neuroimmunol. 2021;356:577600.
    PubMed     Abstract available

  171. MASI G, Spagni G, Campetella L, Monte G, et al
    Assessing the role of a tissue-based assay in the diagnostic algorithm of autoimmune encephalitis.
    J Neuroimmunol. 2021;356:577601.
    PubMed     Abstract available

  172. PAPRI N, Hayat S, Mohammed A, Afsar MNA, et al
    Guillain-Barre syndrome associated with SARS-CoV-2 infection: A case report with long term follow up.
    J Neuroimmunol. 2021;356:577590.
    PubMed     Abstract available

  173. HOU H, Sun Y, Miao J, Gao M, et al
    Ponesimod modulates the Th1/Th17/Treg cell balance and ameliorates disease in experimental autoimmune encephalomyelitis.
    J Neuroimmunol. 2021;356:577583.
    PubMed     Abstract available

  174. SHEIKH AB, Chourasia PK, Javed N, Chourasia MK, et al
    Association of Guillain-Barre syndrome with COVID-19 infection: An updated systematic review.
    J Neuroimmunol. 2021;355:577577.
    PubMed     Abstract available

  175. WANG J, Qiu Z, Li D, Dong H, et al
    Anti-contactin-associated protein-like 2 antibody-associated cerebellar ataxia: A case report and literature review.
    J Neuroimmunol. 2021;353:577515.
    PubMed     Abstract available

  176. ZHANG H, Yang Y, Luo X
    Anti-MOG antibodies associated demyelination following encephalomeningitis: Case report.
    J Neuroimmunol. 2021;353:577519.
    PubMed     Abstract available

  177. LI C, Wang J, Sun X, Li R, et al
    The current situation of diagnosis and treatment of neuromyelitis optica spectrum disorder: Experience with 461 cases from a single centre in South China.
    J Neuroimmunol. 2021;353:577506.
    PubMed     Abstract available

  178. DIEM L, Hoepner R, Bagnoud M, Salmen A, et al
    Natalizumab induced blood eosinophilia: A retrospective pharmacovigilance cohort study and review of the literature.
    J Neuroimmunol. 2021;353:577505.
    PubMed     Abstract available

  179. FANG F, Wang Y, Xu W
    Anti-N-methyl-d-aspartate receptor encephalitis associated with intracranial cryptococcal infection: A case report and 2-year follow-up.
    J Neuroimmunol. 2021;353:577502.
    PubMed     Abstract available

  180. DU Q, Shi Z, Chen H, Zhang Y, et al
    Comparison of clinical characteristics and prognoses in patients with different AQP4-Ab and MOG-Ab serostatus with neuromyelitis optica spectrum disorders.
    J Neuroimmunol. 2021;353:577494.
    PubMed     Abstract available

  181. PRADO MB JR, Narito KM, Adiao KJB
    Anti-GM1 IgM antibody positive axonal variant of Guillain-Barre-syndrome in a pediatric patient with dengue fever.
    J Neuroimmunol. 2021;355:577572.
    PubMed     Abstract available

  182. FAN Z, Zheng D, Wen X, Shen F, et al
    CYP3A5*3 polymorphism and age affect tacrolimus blood trough concentration in myasthenia gravis patients.
    J Neuroimmunol. 2021;355:577571.
    PubMed     Abstract available

  183. DINIZ SN, da Silva CF, de Almeida IT, da Silva Costa FE, et al
    INFbeta treatment affects global DNA methylation in monocytes of patients with multiple sclerosis.
    J Neuroimmunol. 2021;355:577563.
    PubMed     Abstract available

    March 2021
  184. DINOTO A, Bosco A, Sartori A, Bratina A, et al
    Hiccups, severe vomiting and longitudinally extensive transverse myelitis in a patient with prostatic adenocarcinoma and Aquaporin-4 antibodies.
    J Neuroimmunol. 2021;352:577488.
    PubMed     Abstract available

  185. LI X, Hou C, Wu WL, Liang H, et al
    Pediatric anti-N-methyl-d-aspartate receptor encephalitis in southern China: Analysis of 111 cases.
    J Neuroimmunol. 2021;352:577479.
    PubMed     Abstract available

  186. DAY GS, Gordon BA, Bucelli RC, Perrin RJ, et al
    Leveraging molecular biomarkers to make the common diagnosis in the uncommon patient.
    J Neuroimmunol. 2021;352:577474.
    PubMed     Abstract available

  187. COSSU D, Yokoyama K, Sakanishi T, Kuwahara-Arai K, et al
    A mucosal immune response induced by oral administration of heat-killed Mycobacterium avium subsp. paratuberculosis exacerbates EAE.
    J Neuroimmunol. 2021;352:577477.
    PubMed     Abstract available

  188. CHAUDHARY P, Marracci GH, Calkins E, Pocius E, et al
    Thyroid hormone and thyromimetics inhibit myelin and axonal degeneration and oligodendrocyte loss in EAE.
    J Neuroimmunol. 2021;352:577468.
    PubMed     Abstract available

    February 2021
  189. AKAISHI T, Misu T, Takahashi T, Takai Y, et al
    Progression pattern of neurological disability with respect to clinical attacks in anti-MOG antibody-associated disorders.
    J Neuroimmunol. 2021;351:577467.
    PubMed     Abstract available

  190. CHOUDHARY A, Bhargava A, Khichar S, Pradhan S, et al
    Etiological spectrum, clinico-radiological profile and treatment outcomes of longitudinally extensive transverse myelitis - A prospective study from Northwest India.
    J Neuroimmunol. 2021;351:577456.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Autoimmune Disorders is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.